142 related articles for article (PubMed ID: 6157546)
1. Inhibition of cyclic AMP phosphodiesterase activity and myocardial contractility: effects of cilostamide, a novel PDE inhibitor, and methylsiobutylxanthine on rabbit and canine ventricular muscle.
Endoh M; Satoh K; Yamashita S
Eur J Pharmacol; 1980 Aug; 66(1):43-52. PubMed ID: 6157546
[No Abstract] [Full Text] [Related]
2. Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine.
Katano Y; Endoh M
J Cardiovasc Pharmacol; 1992; 20(5):715-22. PubMed ID: 1280732
[TBL] [Abstract][Full Text] [Related]
3. Chronotropic and inotropic actions of amrinone, carbazeran and isobutylmethyl xanthine: role of phosphodiesterase inhibition.
Shahid M; Rodger IW
Br J Pharmacol; 1989 Sep; 98(1):291-301. PubMed ID: 2478244
[TBL] [Abstract][Full Text] [Related]
4. The phosphodiesterase 3 inhibitor cilostamide enhances inotropic responses to glucagon but not to dobutamine in rat ventricular myocardium.
Juan-Fita MJ; Vargas ML; Hernández J
Eur J Pharmacol; 2005 Apr; 512(2-3):207-13. PubMed ID: 15840406
[TBL] [Abstract][Full Text] [Related]
5. EMD 53998 acts as Ca(2+)-sensitizer and phosphodiesterase III-inhibitor in human myocardium.
Uhlmann R; Schwinger RH; Lues I; Erdmann E
Basic Res Cardiol; 1995; 90(5):365-71. PubMed ID: 8585857
[TBL] [Abstract][Full Text] [Related]
6. Multiple molecular forms of phosphodiesterase and the regulation of cardiac muscle contractility.
Weishaar RE; Kobylarz-Singer DC; Quade MM; Steffen RP; Kaplan HR
J Cyclic Nucleotide Protein Phosphor Res; 1986-1987; 11(7):513-27. PubMed ID: 2831259
[TBL] [Abstract][Full Text] [Related]
7. Selective effects of phosphodiesterase inhibitors on different phosphodiesterases, adenosine 3',5'-monophosphate metabolism, and lipolysis in 3T3-L1 adipocytes.
Elks ML; Manganiello VC
Endocrinology; 1984 Oct; 115(4):1262-8. PubMed ID: 6207009
[TBL] [Abstract][Full Text] [Related]
8. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties.
Alvarez R; Banerjee GL; Bruno JJ; Jones GL; Littschwager K; Strosberg AM; Venuti MC
Mol Pharmacol; 1986 Jun; 29(6):554-60. PubMed ID: 3012320
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibitors of specific phosphodiesterases in intact adipocytes.
Manganiello V; Degerman E; Elks M
Methods Enzymol; 1988; 159():504-20. PubMed ID: 2457789
[No Abstract] [Full Text] [Related]
10. Cyclic AMP compartmentation due to increased cAMP-phosphodiesterase activity in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8 (AC8).
Georget M; Mateo P; Vandecasteele G; Lipskaia L; Defer N; Hanoune J; Hoerter J; Lugnier C; Fischmeister R
FASEB J; 2003 Aug; 17(11):1380-91. PubMed ID: 12890691
[TBL] [Abstract][Full Text] [Related]
11. Milrinone, a cyclic AMP-phosphodiesterase inhibitor, has differential effects on regional myocardial work and oxygen consumption in experimental left ventricular hypertrophy.
Chiu WC; Kedem J; Weiss HR; Tse J; Cheinberg BV; Scholz PM
Cardiovasc Res; 1994 Sep; 28(9):1360-5. PubMed ID: 7954646
[TBL] [Abstract][Full Text] [Related]
12. Inotropic responses to selective (RO 20-1724 and SQ 65,442) and nonselective (trequinsin) inhibitors of cyclic AMP-specific class IV phosphodiesterase in newborn, immature, and adult rabbit myocardium.
Oquist NL; Strada SJ; Artman M
Pediatr Res; 1992 Mar; 31(3):300-4. PubMed ID: 1313959
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the relationship between pharmacological inhibition of cyclic nucleotide phosphodiesterase and relaxation of canine tracheal smooth muscle.
Polson JB; Krzanowski JJ; Anderson WH; Fitzpatrick DF; Hwang DP; Szentivanyi A
Biochem Pharmacol; 1979 Apr; 28(8):1391-5. PubMed ID: 87201
[No Abstract] [Full Text] [Related]
14. Phosphodiesterase inhibition by naloxone augments the inotropic actions of beta-adrenergic stimulation.
Park WK; Chang CH; Chae JE; Kim MH; Cho YL; Ahn DS
Acta Anaesthesiol Scand; 2009 Sep; 53(8):1043-51. PubMed ID: 19572940
[TBL] [Abstract][Full Text] [Related]
15. Methylxanthine inhibitors of phosphodiesterases.
Wells JN; Miller JR
Methods Enzymol; 1988; 159():489-96. PubMed ID: 2457788
[No Abstract] [Full Text] [Related]
16. Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit.
Sato S; Talukder MA; Sugawara H; Sawada H; Endoh M
J Mol Cell Cardiol; 1998 Jun; 30(6):1115-28. PubMed ID: 9689586
[TBL] [Abstract][Full Text] [Related]
17. Species-dependent pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 58993 and WIN 62005.
Dundore RL; Pagani ED; Bode DC; Bacon ER; Singh B; Lesher GY; Buchholz RA; Silver PJ
J Cardiovasc Pharmacol; 1995 Jan; 25(1):14-21. PubMed ID: 7723343
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea-pig hearts.
Bethke T; Meyer W; Schmitz W; Scholz H; Stein B; Thomas K; Wenzlaff H
Br J Pharmacol; 1992 Sep; 107(1):127-33. PubMed ID: 1384905
[TBL] [Abstract][Full Text] [Related]
19. Nitric oxide synthase (NOS3) and contractile responsiveness to adrenergic and cholinergic agonists in the heart. Regulation of NOS3 transcription in vitro and in vivo by cyclic adenosine monophosphate in rat cardiac myocytes.
Belhassen L; Kelly RA; Smith TW; Balligand JL
J Clin Invest; 1996 Apr; 97(8):1908-15. PubMed ID: 8621775
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic and pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 63291 and WIN 62582.
Pagani ED; Dundore RL; Bode DC; Bacon ER; Singh B; Lesher GY; Buchholz RA; Silver PJ
J Cardiovasc Pharmacol; 1994 Sep; 24(3):403-10. PubMed ID: 7528296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
